Human medicines
Jakavi
The parallel distributor - "HAEMATO PHARM GmbH" - informed its supplied customers in a letter dated October 8, 2018, that for the two batches of…
Robinul
The marketing authorization holder informed its supplied customers in a letter dated August 16, 2018, that due to quality problems with one batch of…
CO-Valsax and Valsartan-HCT from G.L. Pharma GmbH
The marketing authorization holder informed its supplied customers in a letter dated July 5, 2018, that a production-related impurity occurred at the…
Valsartan medication review - update.
Valsartan and Valsartan/HCT from 1A Pharma GmbH
The marketing authorization holder informed its supplied customers in a letter dated 06.07.2018 that a production-related contamination of the active…
Valsartan and Valsartan/HCT from Sandoz GmbH
In a letter dated July 6, 2018, the marketing authorization holder informed its customers that a production-related contamination of the active…
Recall of drugs containing the active ingredient valsartan from the Chinese manufacturer Zhejiang Huahai Pharmaceutical
Valsartan and Valsarcomp from Genericon Pharma GmbH
The marketing authorization holder has informed its supplied customers in a letter dated July 4, 2018, that the active ingredient valsartan may…
Valsartan and Valsartan-HCT from +pharma arzneimittel gmbh
The marketing authorization holder has informed its supplied customers in a letter dated 04.07.2018 that the active ingredient Valsartan may contain a…
Valsartan and Valsartan HCT from STADA Arzneimittel GmbH
The marketing authorization holder has informed its supplied customers in a letter dated 05.07.2018 that an impurity was detected during the review at…
